Sonoma Biotherapeutics Raises $265 Million In An Oversubscribed Series B Financing To Translate The Promise Of Cell Therapy Into Curative Medicines For Autoimmune And Other Inflammatory Diseases

Aug 04, 2021•over 4 years ago

Amount Raised

$265 Million

Round Type

series b

San FranciscoBiotechnology

Description

Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing. Proceeds from the financing will be used to advance Sonoma Bio’s Treg cell therapy platform and a novel Teff conditioning biologic into the clinic to treat multiple, severe autoimmune and inflammatory diseases and to further invest in and scale up manufacturing operations in order to support supply for initial clinical studies.

Company Information

Company

Sonoma Biotherapeutics

Location

San Francisco, California, United States

About

Sonoma Biotherapeutics is a South San Francisco and Seattle-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. Sonoma Bio has initiated two Phase 1 studies to evaluate the safety and proof-of-mechanism of the company’s lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis and hidradenitis suppurativa. The company has a partnership with Regeneron to discover, develop and commercialize novel regulatory T cell therapies.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Sonoma Biotherapeutics Raises $265 Million In An Oversubscribed Series B Financing To Translate The Promise Of Cell Therapy Into Curative Medicines For Autoimmune And Other Inflammatory Diseases

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information